Cellectar biosciences news

Here are some recent news articles and updates about Cellectar Biosciences:

Recent News

  1. Cellectar Biosciences Reports Positive Interim Results from Phase 1 Clinical Trial of CLR 131 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (February 2023)
    • The company announced positive interim results from its Phase 1 clinical trial of CLR 131, a targeted radiotherapeutic, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
  2. Cellectar Biosciences Presents Data on CLR 131 in Relapsed or Refractory Multiple Myeloma at ASH Annual Meeting (December 2022)
    • The company presented data on CLR 131 in patients with relapsed or refractory multiple myeloma at the American Society of Hematology (ASH) Annual Meeting.
  3. Cellectar Biosciences Appoints New Chief Medical Officer (November 2022)
    • The company appointed Dr. David M. Goldenberg as its new Chief Medical Officer, bringing over 20 years of experience in the pharmaceutical industry.

Recent Updates

  1. CLR 131: Cellectar's lead product candidate, CLR 131, is a targeted radiotherapeutic designed to selectively target and kill cancer cells while minimizing damage to healthy tissues.
  2. Phase 1 Clinical Trials: The company is currently conducting Phase 1 clinical trials of CLR 131 in patients with relapsed or refractory B-cell NHL and multiple myeloma.
  3. Partnership with Pfizer: In 2020, Cellectar entered into a partnership with Pfizer to develop and commercialize CLR 131 in the United States and Canada.

Recent Financials

  1. Q3 2022 Financial Results: Cellectar reported a net loss of $2.3 million for the third quarter of 2022, compared to a net loss of $3.1 million for the same period in 2021.
  2. Cash and Cash Equivalents: As of September 30, 2022, the company had cash and cash equivalents of approximately $14.4 million.

Please note that the news and updates provided are subject to change and may not be comprehensive. It's always a good idea to check the company's website or recent press releases for the most up-to-date information.